Abstract: A plasma display panel includes: pairs of electrodes having first electrode and second electrode which are arranged in parallel with each other; first substrate having dielectric layer formed so that the dielectric layer can cover the pairs of electrodes; and second substrate having third electrode which is arranged crossing the pairs of electrodes, and the plasma display panel further includes: floating electrodes, protruding onto a discharge space provided on dielectric layer at positions respectively corresponding to first electrode and second electrode, wherein floating electrodes are opposed to each other. Due to the above composition, the discharge starting voltage is reduced and the drive voltage is decreased. Accordingly, the light emitting efficiency is enhanced.

Abstract: [Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided. [Means for Solution] The present inventors have conducted extensive studies on EP4 receptor agonists, and as a result, have found that a novel pyridone compound, in which a group having an acidic group is substituted at the 1-position of the pyridone ring, the 6-position is bonded with an aromatic ring group via a linking part, and the linking part contains a nitrogen atom, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action, it is useful as a pharmaceutical, in particular, as an agent for treating peripheral arterial occlusive disease.

Abstract: The present invention aims to improve efficiency of a PDP by providing a material suitable for improving a secondary electron emission coefficient of the PDP. In order to achieve the aim, in a PDP 200, an electron emission layer 20 is formed by dispersing electron emissive particles including a crystalline compound on a protective layer 7 made of MgO. The crystalline compound is, for example, CaSnO3, SrSnO3, BaSnO3, or a solid solution of two or more of them (e.g. (Ca, Sr)SnO3 and (Sr, Ba)SnO3).

Abstract: [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: A plasma display panel includes: pairs of electrodes having first electrode and second electrode which are arranged in parallel with each other; first substrate having dielectric layer formed so that the dielectric layer can cover the pairs of electrodes; and second substrate having third electrode which is arranged crossing the pairs of electrodes, and the plasma display panel further includes: floating electrodes, protruding onto a discharge space provided on dielectric layer at positions respectively corresponding to first electrode and second electrode, wherein floating electrodes are opposed to each other. Due to the above composition, the discharge starting voltage is reduced and the drive voltage is decreased. Accordingly, the light emitting efficiency is enhanced.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: A PDP capable of lowering a discharge initiating voltage with a weak discharge always stabilized during an initialization period even if a Xe partial pressure ratio to a total pressure in discharge gas is increased, improving an image quality with the occurrence of an initializing bright point prevented, preventing the lowering of a light emission efficiency and brightness, and improving brightness; and a production method for simply producing the PDP. The PDP comprises a front panel and a rear panel disposed facing each other with a discharge space provided between them. A fluorescent layer is formed in the area on the discharge space side of the rear panel, and a fluorescent film as a high ? portion is formed in part of the area of its surface. The fluorescent film is formed of a material higher in secondary electron emission coefficient ? than a fluorescent material constituting the fluorescent layer.

Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

Abstract: The invention has succeeded in settling the aforementioned problems by finding that a novel tetrahydropyran derivative has excellent apo B-related lipoprotein secretion-inhibiting activity.

Abstract: The present invention provides methods of fabricating a non-single crystal film, whereby variations in crystal grain size are reduced and the periodicity of grain size is improved. The methods of fabricating a non-single crystal film of the present invention include: first, forming a non-single crystal film and then optimizing laser irradiation by monitoring diffracted light; and second, performing laser irradiation with a substrate having been cooled.

Abstract: A self-emission road device includes light emitting elements and a power unit, and has the light emitting elements emit light through a light emitting face of a protective board set at an upper part of the self-emission road device. For each light emitting face, four emission units are provided. Out of the four emission units, two emission units are designed for a straight road and light beams from these emission units are emitted in a direction whose horizontal component is perpendicular to the light emitting face. Two other emission units are designed for a curve and light beams from these emission units are emitted in a direction whose horizontal component forms a predetermined angle with the direction whose horizontal component is perpendicular to the light emitting face. The emission units for the straight road and curve are set in alternate order.